ProCE Banner Activity

What You Need to Know About Evolving Options for the Treatment of Hemophilia A

Clinical Thought
Building from a solid foundation based on direct factor VIII replacement, management of hemophilia A now includes nonfactor therapies. Here’s my take on progress and future directions.

Released: October 14, 2020

Expiration: October 13, 2021

Share

Faculty

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Sanofi Genzyme Corp

Takeda Pharmaceutical Co Ltd

Faculty Disclosure

Primary Author

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received funds for research support from Genentech/Roche; fees for non-CME/CE services from Bioverativ, Genentech/Roche, and Sanofi; and consulting fees from CSL-Behring, Genentech/Roche, Grifols, Kedrion, Novo Nordisk, Sanofi, Spark, Takeda, and UniQure.